idrevloride

Idrevloride (VX-371) is an investigational, inhaled small-molecule inhibitor of the epithelial sodium channel (ENaC), developed by Parion Sciences in collaboration with Vertex Pharmaceuticals. It is primarily being developed for the treatment of primary ciliary dyskinesia (PCD), a genetic disorder characterized by impaired mucociliary clearance. By blocking ENaC on the airway surface, idrevloride prevents the excessive absorption of sodium and water, thereby increasing the volume of airway surface liquid. This hydration of the mucus layer facilitates easier clearance of secretions. In clinical studies, such as the Phase 2 CLEAN-PCD trial, idrevloride has been evaluated as a nebulized solution, often in conjunction with hypertonic saline, showing significant improvements in lung function.

Other names

idrevloride